Seeking Alpha

Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (GLUE) (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced ...
EurekAlert!

MYC targeting by Omomyc synergizes with PARP inhibition and potentiates antitumor response in preclinical models of triple-negative breast cancer

Results from a VHIO-led study show that MYC targeting by Omomyc induces tumor DNA damage in patient-derived preclinical ...
WWLP-22News

UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- UTR Therapeutics Inc (UTRx Inc.), a drug development biotech company based in New York City, USA is pleased to announce a new milestone, the submission of an ...
Business Wire

Universal DX Initiates Clinical Trial for FDA Approval of Signal-C® Colorectal Cancer Screening Blood Test

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Universal DX (“UDX”), a biotech company dedicated to transforming cancer into a curable disease by detecting it early, today announced closure of the Series B which ...